SMSNA Meeting 

Videos

“Completing those 4 injection cycles is likely to yield the best clinical outcomes for most of our patients,” says Matthew J. Ziegelmann, MD.

Dr. Ziegelmann on Peyronie's disease: “Collagenase remains a very important treatment option”

Articles

"We didn't see any clinically significant changes on the prostate gland, which is very important for the urologists who see people who have prostate cancer or prostate enlargement," says Ronald Swerdloff, MD.

Expert explains latest findings with oral softgel capsule for testosterone replacement therapy

In a recent study presented at the 2021 SMSNA Fall Scientific Meeting, Kevin J. Campbell, MD, MS, and a team of investigators examined the correlations between finasteride and drugs used to treat hypogonadism and sexual dysfunction in order to understand how best to prescribe this medication in terms of lowering adverse drug reactions.

Dr. Campbell discusses SMSNA study on adverse drug reactions associated with finasteride

“Both [IMPRESS trials] would suggest that if patients are motivated to see if they can continue to improve their curvature and avoid things like surgery—which for many patients…is a goal—continuing with the collagenase makes good sense,” says Matthew J. Ziegelmann, MD.

Outcomes show high rates of penile curvature improvement after CCH injections

“Always look at the patient as…a whole and not only [their] testosterone levels,” says Karim Sultan Haider, MD.

Dr. Sultan Haider encourages physicians to examine all types of parameters in patients with hypogonadism

In a recent study presented at the 2021 SMSNA Fall Scientific Meeting, Jay Newmark, MD, MBA, and co-authors report promising findings on the first experiences of patients using JATENZO in the real world.

Dr. Newmark provides updates on FDA-approved oral testosterone undecanoate

“What's most important [is] that…one dose does not just fit all,” says Martin M. Miner, MD.

Dr. Miner emphasizes individualized testosterone therapy dosing

“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.

Oral testosterone undecanoate shows promising results for first use in the real world

In a recent study Martin M. Miner, MD, and co-authors investigated the effect of BMI on the pharmacokinetic profile or dosing of testosterone therapies in men with TD.

Higher testosterone dosing may be required for patients with a higher BMI

“The goal of this study was to look at that original phase 3 trial data [from 2013] and see if we could identify how much change in curvature patients were achieving with each of those 2 injections,” says Matthew J. Ziegelmann, MD.